ELDN biotech catalysts & pipeline

tegoprubart — FDA meeting

2026

• 2026: Receive U.S. Food & Drug Administration ("FDA") guidance on the Phase 3 trial design for kidney transplantation, and subsequently initiate a Phase 3 trial in kidney transplantation.